| SYN004 |
SYN004-001 |
NCT02391727
|
I |
Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors(American trial) |
Ongoing |
| SYN023 |
SYN023-001 |
NA
|
I |
Evaluation of the Safety, Tolerability, Pharmacokinetics and Neutralizing Activity of Single, Escalating, Intramuscular Injection Doses of SYN023 in Healthy Adult Volunteers. |
Completed |
| SYN023 |
SYN023-002 |
NCT02956746
|
II |
A Phase 2 randomized blinded single dose comparison of the safety, pharmacokinetics, and pharmacodynamics of rabies immune globulin, and SYN023 in healthy adult subjects receiving rabies vaccines |
Completed |
| SYN008 |
S08-01 |
NA
|
I |
A Phase I randomized blinded single dose comparison of the safety pharmacokinetics and pharmacodynamics of SYN008 and omalizumab (Xolair) in healthy adult subjects |
Ongoing |
| SYN050 |
160045 |
NA
|
I |
Randomized, double-blind, parallel study evaluating the pharmacokinetic similarity of SYN050 (Synermore biologics bevacizumab) and Avastin, following a single i.v. dose of 2 mg/kg in healthy male volunteers(New Zealand Trial) |
Ongoing |
| SYN060 |
SYN060-001 |
NCT03254810
|
I |
A phase 1 comparison evaluation of safety and pharmacokinetics between SYN060 and Adalimumab (Humira) in healthy adults subjects (Australian trial) |
Ongoing |
| SYN023 |
SYN023-003 |
NA
|
Ib |
A phase 1 evaluation of the safety, pharmacokinetics and pharmacodynamics of single intramuscular and subcutaneous doses of SYN023 in healthy adult subjects(American trial) |
Completed |
| SYN023 |
SYN023-005 |
NA
|
Ia/Ib |
A phase I bridging clinical trial of safety, pharmacokinetics and pharmacodynamics of single-center, open, randomized single intramuscular dose of SYN023 in healthy adult subjects（Chinese Trial） |
Ongoing |
| SYN004 |
RG01N-1829 |
NA
|
Ia |
A phase I clinical trial of tolerability, pharmacokinetics and safety of SYN004 with solid tumors（Chinese Trial） |
Ongoing |
